Kamada Ltd. (TLV:KMDA)
2,135.00
-22.00 (-1.02%)
Jun 8, 2026, 2:51 PM IDT
Kamada Revenue
Kamada had revenue of $45.24M USD in the quarter ending March 31, 2026, with 2.78% growth. This brings the company's revenue in the last twelve months to $136.97M, up 9.75% year-over-year. In the year 2025, Kamada had annual revenue of $180.46M with 12.12% growth.
Revenue (ttm)
$136.97M
Revenue Growth
+9.75%
P/S Ratio
2.17
Revenue / Employee
$296.48K
Employees
462
Market Cap
1.24B ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 180.46M | 19.51M | 12.12% |
| Dec 31, 2024 | 160.95M | 18.43M | 12.93% |
| Dec 31, 2023 | 142.52M | 13.18M | 10.19% |
| Dec 31, 2022 | 129.34M | 25.70M | 24.79% |
| Dec 31, 2021 | 103.64M | -29.60M | -22.22% |
| Dec 31, 2020 | 133.25M | 6.06M | 4.76% |
| Dec 31, 2019 | 127.19M | 12.72M | 11.11% |
| Dec 31, 2018 | 114.47M | 11.64M | 11.32% |
| Dec 31, 2017 | 102.83M | 25.33M | 32.69% |
| Dec 31, 2016 | 77.49M | 7.59M | 10.85% |
| Dec 31, 2015 | 69.91M | -1.16M | -1.63% |
| Dec 31, 2014 | 71.07M | 442.00K | 0.63% |
| Dec 31, 2013 | 70.62M | -2.05M | -2.82% |
| Dec 31, 2012 | 72.68M | 13.19M | 22.18% |
| Dec 31, 2011 | 59.48M | 25.01M | 72.53% |
| Dec 31, 2010 | 34.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 54.78B |
| Rekah Pharmaceutical Industry | 304.15M |
| Seach Medical Group | 275.29M |
| InterCure | 270.20M |
| Together Pharma | 109.63M |
| Tikun Olam-Cannbit Pharmaceuticals | 9.10M |
| Nextage Therapeutics | 243.00K |
Kamada News
- 6 days ago - Kamada (KMDA) Receives FDA Nod for New Fluorescent Focus Inhibition Test - GuruFocus
- 6 days ago - Kamada Receives FDA Approval For In-House Rabies Virus Neutralization Testing Laboratory - Nasdaq
- 7 days ago - Kamada gets FDA approval for Rapid Fluorescent Focus Inhibition Test laboratory - TheFly
- 7 days ago - Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory - GlobeNewsWire
- 25 days ago - Kamada (KMDA) Q1 2026 Earnings Transcript - The Motley Fool
- 25 days ago - Kamada Q1 Earnings Call Highlights - MarketBeat
- 25 days ago - Kamada Falls Short on Q1 2026: $0.07 EPS vs $0.12 Expected - AlphaStreet
- 25 days ago - Kamada (KMDA) Maintains 2026 Financial Projections - GuruFocus